Core Points - The article discusses the importance of enabling Javascript and cookies in browsers to avoid access issues [1] - It highlights that ad-blockers may prevent users from proceeding to the desired content [1] Summary by Category - **Technical Requirements** - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to access restrictions, necessitating their temporary disablement [1]

Core Insights - Twist Bioscience Corporation is a significant player in the biotech industry, focusing on synthetic DNA-based products and services for various fields, including healthcare and agriculture [1] Financial Performance - For Q4 2025, the company reported an earnings per share (EPS) of -$0.44, which was better than the estimated EPS of -$0.50, but slightly higher than the Zacks Consensus Estimate of a $0.40 loss [2][6] - The revenue for the quarter was approximately $99 million, surpassing the estimated revenue of $97.4 million and marking a significant increase from $84.71 million reported in the same quarter last year [3][6] - Twist Bioscience has consistently exceeded consensus revenue estimates over the past four quarters [3] Valuation Metrics - The company's price-to-earnings (P/E) ratio is approximately -20.42, indicating negative earnings, while the price-to-sales ratio is about 4.21, suggesting investor confidence in the company's revenue potential [4][6] Financial Health - Twist Bioscience maintains a low debt-to-equity ratio of about 0.16 and a current ratio of approximately 3.64, indicating a strong ability to cover short-term liabilities [5]

Core Insights - Twist Bioscience Corporation reported a mixed performance for the fourth quarter, with a loss of 45 cents per share, slightly worse than the consensus estimate of a 43-cent loss, while sales reached $99.01 million, up 17% year over year, exceeding the consensus of $97.32 million [1][2] Financial Performance - The adjusted EBITDA loss for the fourth quarter was $7.8 million, an improvement from a loss of $17 million a year ago [1] - Gross margin for the fourth quarter increased to 51.3%, compared to 45.1% a year ago [2] Customer and Product Metrics - The company shipped products to approximately 3,800 customers in 2025, up from about 3,550 the previous year [2] - Twist shipped approximately 938,000 genes, an increase from approximately 772,000 genes a year ago [2] Future Outlook - For fiscal 2026, Twist Bioscience expects sales between $425 million and $435 million, significantly higher than the consensus of $374.69 million [3] - The guidance includes revenue expectations of approximately $194 million to $199 million from DNA Synthesis and Protein Solutions, and $231 million to $236 million from NGS Applications [3] - Gross margin is anticipated to be above 52% for fiscal 2026 [3] - For the first quarter of 2026, sales are projected to be between $100 million and $101 million, compared to the consensus of $100.34 million [3] Strategic Goals - The company aims to achieve adjusted EBITDA breakeven by the fourth quarter of fiscal 2026, entering a new growth phase [4] - CEO Emily M. Leproust emphasized the goal of maintaining gross margins above 50% and moving towards sustained profitable growth [4] Analyst Perspective - William Blair noted that shares of Twist trade at 3.9 times its calendar 2026 sales target, below the average of 6.3 times for high-growth life science tools peers [5] - Analyst Matt Larew expressed confidence in the long-term revenue growth trajectory, highlighting the company's aggressive investments in multiple markets, which could lead to over 20% growth [5] - The company’s strategy to moderate investments while aiming for adjusted EBITDA breakeven is seen as a positive move [6]

Financial Data and Key Metrics Changes - The company reported a record revenue of $99 million for Q4, representing a 17% year-over-year increase and marking the 11th consecutive quarter of growth [7] - For the full year, revenue reached $376.6 million, a growth of 20% over fiscal 2024 [7][23] - Gross margin for Q4 was 51.3%, and for the full year, it was 50.7%, an increase from 42.6% in fiscal 2024 [7][23] - Adjusted EBITDA loss improved to approximately $7.8 million for Q4 and $46.9 million for the full year, showing significant improvement compared to fiscal 2024 [27][28] Business Line Data and Key Metrics Changes - SynBio revenue for Q4 was $39.5 million, up 17% year-over-year, and for the full year, it increased to $145 million, also a 17% growth [8][23] - NGS revenue for Q4 grew to approximately $53 million, a 16% increase year-over-year, and for the full year, it reached $208.1 million, a growth of 23% [12][24] - Biopharma revenue was $6.4 million for Q4, a 22% increase year-over-year, with full-year revenue at $23.5 million, a growth of 15% [14][24] Market Data and Key Metrics Changes - Revenue from the Americas increased to approximately $57.3 million in Q4, a 9% year-over-year growth, while EMEA revenue rose to $34.6 million, a 35% increase [25] - APAC revenue increased to $7.2 million in Q4, a 9% year-over-year growth [25] - China accounted for approximately 1% of total revenue for fiscal 2025, indicating a relatively small market share [25] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven by the end of fiscal 2026, focusing on setting the stage for future growth acceleration [8] - A new product introduction for NGS aimed at minimal residual disease (MRD) is expected to launch commercially in early 2026, enhancing the company's offerings in cancer diagnostics [18][21] - The company plans to combine SynBio and Biopharma revenue reporting under the term DNA Synthesis and Protein Solutions to better reflect its customer base and operational synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in AI-enabled drug discovery, with significant orders from customers in this area [10][29] - The company anticipates total revenues of $425 million to $435 million for fiscal 2026, reflecting a growth of approximately 13% to 15.5% year-over-year [29] - Management emphasized the importance of staying close to customers to anticipate emerging needs and drive product innovation [32] Other Important Information - The company ended fiscal 2025 with cash, cash equivalents, and short-term investments of approximately $232.4 million [28] - Capital expenditures for fiscal 2025 were $28 million, reflecting investments in growth for the upcoming fiscal year [28] Q&A Session Summary Question: On gross margins and pricing - Management indicated that gross margin expectations are influenced by customer mix and that they expect to maintain a strong margin trajectory moving forward [36][37] Question: NGS growth expectations - Management clarified that NGS growth is expected to rebound to 20% by Q4 2026, with a significant customer ramp anticipated [39][40] Question: Biopharma order sustainability - Management expressed optimism about the sustainability of AI-driven orders and the close ties between Biopharma and SynBio offerings [41][42] Question: Guidance for gross margins - Management expects gross margins to improve throughout fiscal 2026, driven by revenue growth and continuous process improvements [44][45] Question: Market opportunity definition - Management acknowledged the need for clearer market opportunity definitions and metrics to help investors understand growth potential [60][63]

Financial Data and Key Metrics Changes - The company reported a record revenue of $99 million for Q4, representing a 17% year-over-year increase and marking the 11th consecutive quarter of growth [7] - For the full fiscal year 2025, revenue reached $376.6 million, a growth of 20% compared to fiscal 2024 [7][23] - Gross margin for Q4 was 51.3%, and for the full year, it was 50.7%, an increase from 42.6% in fiscal 2024 [7][23] Business Line Data and Key Metrics Changes - Synbio revenue for Q4 was $39.5 million, up 17% year-over-year, and for the full year, it increased to $145 million from $123.5 million in fiscal 2024 [8][23] - NGS revenue for Q4 grew to approximately $53 million, a 16% increase year-over-year, with full-year revenue at $208.1 million, reflecting a 23% growth [12][24] - Biopharma revenue for Q4 was $6.4 million, a 22% increase year-over-year, with full-year revenue at $23.5 million, a 15% growth [14][24] Market Data and Key Metrics Changes - Revenue from the Americas increased to approximately $57.3 million in Q4, a 9% year-over-year growth, while EMEA revenue rose to $34.6 million, a 35% increase [25] - APAC revenue increased to $7.2 million in Q4, a 9% year-over-year growth [25] Company Strategy and Development Direction - The company plans to combine Synbio and Biopharma revenue reporting under the term "DNA synthesis and protein solutions" to better reflect its customer base [16] - A focus on AI-driven drug discovery is expected to drive future growth, with significant orders from customers in this area [10][29] - The introduction of the MRD Express product is aimed at enhancing cancer diagnostics and treatment, with a commercial launch expected in early 2026 [18][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth opportunities, particularly in AI-enabled drug discovery and the integration of Synbio and Biopharma services [10][32] - The company anticipates total revenues for fiscal 2026 to be between $425 million and $435 million, reflecting a growth of approximately 13% to 15.5% year-over-year [29] Other Important Information - The company ended fiscal 2025 with cash, cash equivalents, and short-term investments of approximately $232.4 million [28] - Adjusted EBITDA for Q4 was a loss of approximately $7.8 million, an improvement of $9.2 million compared to Q4 of fiscal 2024 [27] Q&A Session Summary Question: On gross margins and pricing - Management indicated that while they expect to maintain strong gross margins, specific customer mix may influence quarterly results [36][37] Question: NGS growth expectations - Management expects NGS growth to return to 20% by Q4, driven by customer transitions and new product introductions [38] Question: Sustainability of AI-driven biopharma orders - Management remains optimistic about the biopharma business, highlighting the close ties to Synbio offerings and the potential of AI [40][41] Question: Guidance for gross margins and NGS portfolio - Management anticipates improvements in gross margins throughout the year, driven by revenue growth and continuous process improvements [43][44] Question: Market opportunity definition - Management acknowledged the need for clearer market definitions and metrics to help investors understand growth potential [59][62]

Financial Data and Key Metrics Changes - The company reported a record revenue of $99 million for Q4 2025, representing a 17% year-over-year increase and marking the 11th consecutive quarter of growth [5][21] - For the full fiscal year 2025, total revenue reached $376.6 million, a growth of 20% compared to fiscal 2024 [5][21] - Gross margin for Q4 was 51.3%, while the full-year gross margin was 50.7%, an increase from 42.6% in fiscal 2024 [5][21] Business Line Data and Key Metrics Changes - Synbio revenue for Q4 was $39.5 million, up 17% year-over-year, and for the full year, it increased to $145 million from $123.5 million in fiscal 2024 [6][21] - NGS revenue for Q4 grew to approximately $53 million, a 16% increase year-over-year, with full-year revenue reaching $208.1 million, a growth of 23% [10][22] - Biopharma revenue was $6.4 million for Q4, reflecting a 22% increase year-over-year, with full-year revenue at $23.5 million, a growth of 15% [12][22] Market Data and Key Metrics Changes - Revenue from the Americas increased to approximately $57.3 million in Q4, a 9% year-over-year growth, while EMEA revenue rose to $34.6 million, a 35% increase [23] - APAC revenue increased to $7.2 million in Q4, a 9% year-over-year growth, with China accounting for approximately 1% of total revenue for fiscal 2025 [23] Company Strategy and Development Direction - The company plans to combine Synbio and Biopharma revenue reporting under the term "DNA synthesis and protein solutions" to better reflect its customer base and operational synergies [14] - A focus on AI-driven drug discovery is expected to drive future growth, with significant orders from customers in this area [8][22] - The introduction of the MRD Express product is aimed at enhancing cancer diagnostics and treatment, with a planned commercial launch in early 2026 [16][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, expecting total revenues for fiscal 2026 to be between $425 million and $435 million, reflecting a year-over-year growth of approximately 13% to 15.5% [27] - The company anticipates achieving adjusted EBITDA breakeven by the end of fiscal 2026, with gross margins expected to remain above 52% [28][29] Other Important Information - The company ended fiscal 2025 with cash, cash equivalents, and short-term investments of approximately $232.4 million [25] - Adjusted EBITDA for Q4 was a loss of approximately $7.8 million, an improvement of $9.2 million compared to Q4 of fiscal 2024 [24] Q&A Session Summary Question: On gross margins and pricing dynamics - Management noted that while they expect to maintain strong gross margins, specific customer mix and tough comparisons from previous quarters may impact short-term results [33][34] Question: Guidance for NGS growth - Management clarified that the NGS guidance reflects a temporary air pocket due to customer transitions, with expectations of returning to 20% growth by Q4 2026 [35][36] Question: Insights on Synbio and biopharma orders - Management highlighted the strategic importance of biopharma and the positive momentum driven by AI, indicating strong future growth potential [37] Question: Market opportunity and revenue per assay - Management acknowledged the need for clearer metrics on market size and penetration, indicating that they are working on providing better insights for investors [55][58]

Fiscal 2025 4Q and Full Year Financial Results N O V E M B E R 2 0 2 5 Agenda Welcome Angela Bitting SVP, Corporate Affairs Quarterly Highlights Emily Leproust Chief Executive Officer Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive Officer Q&A Session 2 | TWIST BIOSCIENCE | PROPRIETARY Legal Disclaimers This presentation contains forward-looking statements. All statemen ...

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Revenue Growth - Record revenue of $376.6 million in Fiscal 2025, an increase of 20% from $313.0 million in Fiscal 2024[1] - Q4FY25 revenue reached $99.0 million, up 17% from $84.7 million in Q4FY24, marking the 11th consecutive quarter of sequential growth[1] - SynBio revenue grew 17% to $145.0 million in FY25 compared to $123.5 million in FY24[3] - NGS revenue increased by 23% to $208.1 million in FY25 from $169.1 million in FY24[3] - Biopharma revenue rose 15% to $23.5 million in FY25 compared to $20.3 million in FY24[3] - For FY26, total revenue is expected to be between $425 million and $435 million, representing a growth of 13% to 15.5% year-over-year[10] - Revenues for the three months ended September 30, 2025, increased to $99,009,000, up 16.9% from $84,710,000 in 2024[22] Profitability and Margins - Gross margin improved to 50.7% in FY25, an increase of 8.1 percentage points from 42.6% in FY24[1] - Gross margin for FY26 is projected to be above 52%[10] - Adjusted EBITDA for FY25 was $(46.9) million, an improvement from $(93.5) million in FY24[5] - Adjusted EBITDA for the three months ended September 30, 2025, was $(7,848,000), an improvement from $(17,042,000) in 2024[26] Expenses and Losses - Net loss attributable to common stockholders for the three months ended September 30, 2025, was $27,138,000, compared to a loss of $34,655,000 in 2024, representing a 21.5% improvement[22] - Research and development expenses for the three months ended September 30, 2025, were $17,014,000, down 19.5% from $21,134,000 in 2024[22] - Selling, general and administrative expenses increased to $63,758,000 for the three months ended September 30, 2025, up 19.9% from $53,143,000 in 2024[22] Assets and Liabilities - Total current assets decreased to $332,966,000 as of September 30, 2025, from $346,776,000 in 2024, a decline of 4.0%[24] - Total liabilities increased to $168,903,000 as of September 30, 2025, compared to $141,634,000 in 2024, an increase of 19.2%[24] - Cash and cash equivalents decreased to $183,049,000 as of September 30, 2025, down from $226,316,000 in 2024, a decrease of 19.1%[24] Other Financial Highlights - The company shipped approximately 938,000 genes in FY25, up from approximately 772,000 in FY24[9] - The company reported a gain on the sale of business amounting to $48,847,000 for the twelve months ended September 30, 2025[22] - The weighted average shares used in computing net loss per share attributable to common stockholders increased to 60,424,000 in 2025 from 58,554,000 in 2024[22]

Core Insights - Twist Bioscience Corporation announced its financial results for the fourth quarter and full year of fiscal 2025, ending September 30, 2025 [1] Financial Results - The company will issue its financial results before the market opens on November 14, 2025, and will hold a conference call at 8:00 a.m. Eastern Time to discuss these results [10] Business Highlights - Twist Bioscience focuses on providing synthetic DNA tools for various fields including medicine, agriculture, industrial chemicals, and defense, aiming to improve lives and sustainability [4] - The company utilizes an innovative silicon-based DNA Synthesis Platform that offers precision and efficiency in synthesis, sequencing, and therapeutics discovery [5] Upcoming Events - Emily M. Leproust, Ph.D., CEO, and Adam Laponis, CFO, will participate in a fireside chat at the 7th Annual Wolfe Research Healthcare Conference on November 17, 2025 [8]